Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others.

Pharmaceutical

Olatec Therapeutics

Damaris B. Skouras

Piscitelli Philip

Jeanette Rooney, CPA, CGMA

Cynthia (Dana) Barrow

Mustafa Noor

Joseph St. Laurent

Charles A. Dinarello

The Clinical Advisors team at Olatec Therapeutics provides expert guidance on the design and execution of clinical trials for the company's NLRP3 antagonist therapeutics. They collaborate with cross-functional teams to ensure that clinical strategies align with regulatory requirements and scientific goals, while also interpreting clinical data to inform the development of treatments for inflammatory diseases. Their insights help drive the advancement of innovative therapies from the lab to clinical practice.

Clinical Advisors

Scientific Advisors

Leadership Team

Clinical Advisors

About

Team members

Other teams at Olatec Therapeutics

Scientific Advisors

Leadership Team